ascopubs.org

Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus ...

Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab ...